Keyphrases
Randomized Controlled Trial
100%
Bladder Cancer
100%
Patient-reported Outcomes
100%
Oncological Treatment
100%
Control Arm
44%
Overall Survival
33%
Hospitalization
22%
Advanced or Metastatic
22%
Standard of Care
22%
Chemoimmunotherapy
22%
Metastatic Bladder Cancer
22%
Locally Advanced Bladder Cancer
22%
Hospital Admission
11%
Clinical Effect
11%
Quality of Life
11%
Cancer Diagnosis
11%
Inclusion Criteria
11%
Patient Selection
11%
Treatment Efficacy
11%
Hospital Treatment
11%
Cancer Patients
11%
Once-weekly
11%
Oncology
11%
Dose Reduction
11%
Metastatic Disease
11%
Time Response
11%
Clinical Endpoints
11%
Treatment Survival
11%
Co-primary
11%
EORTC QLQ-C30
11%
Effect Control
11%
Treatment Completion
11%
Common Terminology Criteria for Adverse Events (CTCAE)
11%
Quality of Survival
11%
Clinical Visit
11%
Active Use
11%
Real-time Warning
11%
Alert Algorithm
11%
Medicine and Dentistry
Randomized Controlled Trial
100%
Arm
100%
Cancer Therapy
100%
Bladder Cancer
100%
Patient-Reported Outcome
100%
Clinician
30%
Overall Survival
30%
Side Effect
20%
Immunotherapy
20%
Metastatic Bladder Cancer
20%
Quality of Life
10%
Symptom
10%
Metastatic Carcinoma
10%
Oncology
10%
Cancer Diagnosis
10%
Clinical Endpoint
10%
Drug Dose Reduction
10%
Nursing and Health Professions
Patient-Reported Outcome
100%
Cancer Therapy
100%
Bladder Cancer
100%
Clinician
33%
Overall Survival
33%
Side Effect
22%
Health Care Quality
22%
Compliance
22%
Immunotherapy
22%
Symptom
11%
Quality of Life
11%
Cancer Diagnosis
11%
Hospital
11%
Drug Dose Reduction
11%
Metastasis
11%
Treatment Response Time
11%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Bladder Cancer
100%
Overall Survival
60%
Side Effect
40%
Chemotherapy
40%
Immunotherapy
40%
Malignant Neoplasm
20%
Symptom
20%
Metastasis
20%